The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...

The company believes Chinese authorities are probing allegations that two current and two former employees had illegally ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

AstraZeneca Plc is increasingly looking to the United States for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drug maker’s share price ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...